299 related articles for article (PubMed ID: 31911549)
1. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J
Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933
[TBL] [Abstract][Full Text] [Related]
4. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
5. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
Galetta D; Catino A; Misino A; Logroscino A; Fico M
Tumori; 2016; 102(2):127-30. PubMed ID: 26108245
[TBL] [Abstract][Full Text] [Related]
6. Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells.
Manente AG; Pinton G; Zonca S; Cilli M; Rinaldi M; Daga A; Nilsson S; Moro L
Oncotarget; 2015 Sep; 6(28):25121-34. PubMed ID: 26208479
[TBL] [Abstract][Full Text] [Related]
7. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
8. Synchronous pleural and peritoneal malignant mesothelioma: a case report and review of literature.
Del Gobbo A; Fiori S; Gaudioso G; Bonaparte E; Tabano S; Palleschi A; Bosari S; Ferrero S
Int J Clin Exp Pathol; 2014; 7(5):2484-9. PubMed ID: 24966960
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K; Hoda MA; Klikovits T; Münzker J; Ghanim B; Wagner C; Garay T; Laszlo V; Setinek U; Dome B; Filipits M; Pirker C; Heffeter P; Selzer E; Tovari J; Torok S; Kenessey I; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedus B; Grusch M
Am J Respir Crit Care Med; 2014 Oct; 190(7):763-72. PubMed ID: 25188816
[TBL] [Abstract][Full Text] [Related]
10. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
13. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
14. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
15. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
17. Searching for targets for the systemic therapy of mesothelioma.
Stahel RA; Weder W; Felley-Bosco E; Petrausch U; Curioni-Fontecedro A; Schmitt-Opitz I; Peters S
Ann Oncol; 2015 Aug; 26(8):1649-60. PubMed ID: 25722383
[TBL] [Abstract][Full Text] [Related]
18. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
19. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
Echeverry N; Ziltener G; Barbone D; Weder W; Stahel RA; Broaddus VC; Felley-Bosco E
Cell Death Dis; 2015 May; 6(5):e1757. PubMed ID: 25950487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
